The Relationship Between the Gut Microbiome and Management of C. Difficile
EP. 1: C Difficile Infection: The Importance of the Gut Microbiome
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS Opening their discussion on Clostridioides difficile, experts provide an overview on the gut microbiome and colonization resistance.
EP. 2: C Difficile Infection: What Causes Disruption of the Gut Microbiome?
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS Shared insight on how disruption of the gut microbiome may occur based on antibiotic exposure, environmental factors, and diet.
EP. 3: Understanding How Disruption of the Gut Microbiome Leads to CDI
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS The panel reflects on how disruption of the gut microbiome leads to the proliferation of Clostridioides difficile.
EP. 4: Identifying CDI: Presentation, Prevalence, and Spectrum of Disease
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS Comprehensive discussion on the identification of Clostridioides difficile infection, the spectrum of disease, and overall epidemiology.
EP. 5: Who Is at Risk for Developing Clostridioides Difficile Infection?
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS An overview of the risk factors that contribute to the development of Clostridioides difficile infection in various health care settings.
EP. 6: Impact of Therapies on Clostridioides Difficile Infection Development
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS Experts review the impact that medications, antibiotic or otherwise, may have on the development of Clostridioides difficile infection.
EP. 7: Identification and Management of Recurrent C Difficile Infection
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS Shared insight on the prevalence of recurring Clostridioides difficile infection and management strategies.
EP. 8: Antibiotics for CDI: Administration Strategies and Treatment Guidelines
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS Experts consider optimal approaches to administering therapy for CDI and share insight on available treatment guidelines.
EP. 9: A Patient Case of C Difficile Infection: Selecting Optimal Therapy
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS Centering their discussion around a patient case of CDI, experts discuss optimal therapy selection given available agents and guidelines.
EP. 10: Selecting Therapy for Recurrent CDI: The Potential for FMT
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS The panel considers optimal therapy for recurrent CDI, particularly the role of fecal microbiota transplantation.
EP. 11: Addressing the Barriers to Fecal Microbiota Transplantation in CDI
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS Experts reflect on the barriers to utilizing fecal microbiota transplantation therapy in Clostridioides difficile infection.
EP. 12: Results of the PUNCH CD3 Trial: RBX2660 in Recurrent CDI
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS Shared insight on the phase 3 data behind RBX2660, a novel FMT therapy for patients with recurrent Clostridioides difficile infection.
EP. 13: Results of the ECOSPOR-III Trial: SER-109 in Recurrent CDI
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS The panel reviews phase 3 data behind SER-109, another novel FMT therapy for patients with recurrent Clostridioides difficile infection.
EP. 14: Practical Advice on Novel Fecal Microbiota Transplantation in CDI
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS Practical considerations for the future use of novel FMT therapy for patients with recurrent Clostridioides difficile infection.
EP. 15: Looking Toward the Future of CDI Management
ByJames A. McKinnell, MD,Carl V. Crawford, MD,Sahil Khanna, MBBS, MS,Kelly R. Reveles, PharmD, PhD, BCPS Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.
